术前循环肿瘤DNA预测高危III期皮肤黑色素瘤患者的生存
研究对174例接受完整淋巴结清扫的III期皮肤黑色素瘤患者术前血液标本进行ctDNA分析,发现可检测到ctDNA与更差的黑素瘤特异性生存显著相关(发现队列HR 2.11,P<0.01;验证队列HR 2.29,P=0.04),多变量分析中仍显著(HR 1.85,P=0.04),且独立于III期亚分期。
要点
- 术前可检测ctDNA与更差的黑素瘤特异性生存显著相关,多变量分析HR 1.85(P=0.04)。
- ctDNA在发现队列和验证队列的检出率分别为34%和33%。
- ctDNA可在AJCC III期亚分期基础上进一步细分患者,期别越晚关联越显著。
核心结论
- 术前ctDNA可预测接受完整淋巴结清扫的高危III期黑色素瘤患者的黑素瘤特异性生存,且独立于III期亚分期。
- 该生物标志物可能在判断预后和为辅助治疗分层患者方面有重要作用。
研究设计与样本
- 对174例接受完整淋巴结清扫的III期黑色素瘤患者术前采集的血液标本进行ctDNA分析。
- 采用Cox回归分析评估ctDNA对远处转移无复发生存和黑素瘤特异性生存的预后意义。
主要发现
- 发现队列和验证队列中ctDNA检出率分别为34%和33%。
- ctDNA检出与更大的淋巴结黑色素瘤沉积、更多受累淋巴结数、更晚分期和高乳酸脱氢酶水平相关。
- 可检测ctDNA与更差的黑素瘤特异性生存显著相关:发现队列HR 2.11(P<0.01),验证队列HR 2.29(P=0.04)。
- 多变量分析中ctDNA仍显著相关(HR 1.85,P=0.04)。
- ctDNA可在AJCC III期亚分期基础上进一步细分患者,期别越晚关联越显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The outcomes of patients with stage III cutaneous melanoma who undergo complete surgical resection can be highly variable, and estimation of individual risk of disease recurrence and mortality remains imprecise. With recent demonstrations of effective adjuvant targeted and immune checkpoint inhibitor therapy, more precise stratification of patients for costly and potentially toxic adjuvant therapy is needed. We report the utility of pre-operative circulating tumour DNA (ctDNA) in patients with high-risk stage III melanoma. PATIENTS AND METHODS: ctDNA was analysed in blood specimens that were collected pre-operatively from 174 patients with stage III melanoma undergoing complete lymph node (LN) dissection. Cox regression analyses were used to evaluate the prognostic significance of ctDNA for distant metastasis recurrence-free survival and melanoma-specific survival (MSS). RESULTS: The detection of ctDNA in the discovery and validation cohort was 34% and 33%, respectively, and was associated with larger nodal melanoma deposit, higher number of melanoma involved LNs, more advanced stage and high lactate dehydrogenase (LDH) levels. Detectable ctDNA was significantly associated with worse MSS in the discovery [hazard ratio (HR) 2.11 P < 0.01] and validation cohort (HR 2.29, P = 0.04) and remained significant in a multivariable analysis (HR 1.85, P = 0.04). ctDNA further sub-stratified patients with AJCC stage III substage, with increasing significance observed in more advanced stage melanoma. CONCLUSION: Pre-operative ctDNA predicts MSS in high-risk stage III melanoma patients undergoing complete LN dissection, independent of stage III substage. This biomarker may have an important role in determining prognosis and stratifying patients for adjuvant treatment.
引用
- Lee JH, Saw RP, Thompson JF, et al. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Ann Oncol. 2019. PMID: 30860590. doi:10.1093/annonc/mdz075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。